| Adherence rates with infliximab therapy in Crohn's disease. | |
| | |
MedLine Citation:
|
PMID: 16984504 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
BACKGROUND: Inflammatory bowel disease is associated with non-adherence to treatment with oral medications. AIM: To assess the intravenous infliximab adherence rate and identify risk factors for non-adherence to treatment. METHODS: Infliximab infusion dates for 1 June 2002-30 October 2003 were obtained. Additional information was obtained from two other administrative and patient-based databases. Non-adherence was defined as a 'No Show' designation for a scheduled appointment. Non-adherence rate, odds ratios for associations to 'No Show' appointments and analysis were performed to identify patient characteristics associated with non-adherent behaviour. RESULTS: One thousand hundred and eighty-five infliximab infusions were scheduled for 274 patients. Forty-eight (4%) of appointments were classified as 'No Show'. Six patients accounted for 13/48 (27%) of failed appointments; another 35 patients missed one appointment. 'No Show' appointments were more likely to be for female patients, those on concomitant immunomodulators and those >18 weeks from initial infusion. Patients who missed >1 appointment were more likely to be female and have Medicaid vs. those with only one missed appointment (P < 0.05). Indication, patient area code and race were not significantly associated with single or repeated No Show behaviour. CONCLUSIONS: Overall, the non-adherence rate for infliximab is low. Risk factors that may contribute to non-adherence to treatment include female gender and maintenance dosing. |
| | |
Authors:
|
S Kane; L Dixon |
Related Documents
:
|
16925904 - Effective role redesign: an audit of outcomes following the introduction of a new nurse... 3452374 - Family practice physicians' beliefs, attitudes, and practices regarding obesity. 17145904 - Participation of french general practitioners in end-of-life decisions for their hospit... 18197544 - Patient education: an efficient adjuvant therapy for hyperphosphatemia in hemodialysis ... 21719884 - Clinical effect of increasing doses of lenalidomide in high-risk myelodysplastic syndro... 8416634 - Diagnostic success of bronchoscopic biopsy in immunocompromised patients with acute pul... |
Publication Detail:
|
Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't |
Journal Detail:
|
Title: Alimentary pharmacology & therapeutics Volume: 24 ISSN: 0269-2813 ISO Abbreviation: Aliment. Pharmacol. Ther. Publication Date: 2006 Oct |
Date Detail:
|
Created Date: 2006-09-20 Completed Date: 2007-05-21 Revised Date: 2007-12-03 |
Medline Journal Info:
|
Nlm Unique ID: 8707234 Medline TA: Aliment Pharmacol Ther Country: England |
Other Details:
|
Languages: eng Pagination: 1099-103 Citation Subset: IM |
Affiliation:
|
Department of Medicine, University of Chicago, Chicago, IL 60637, USA. skane@medicine.bsd.uchicago.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adolescent Adult Aged Anti-Inflammatory Agents / therapeutic use* Antibodies, Monoclonal / therapeutic use* Appointments and Schedules Crohn Disease / therapy* Female Humans Male Middle Aged Patient Compliance / statistics & numerical data* |
| Grant Support | |
ID/Acronym/Agency:
|
P30 DK42086/DK/NIDDK NIH HHS |
| Chemical | |
Reg. No./Substance:
|
0/Anti-Inflammatory Agents; 0/Antibodies, Monoclonal; 0/infliximab |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Once daily MMX mesalazine for the treatment of mild-to-moderate ulcerative colitis: a phase II, dose...
Next Document: The +1059G/C polymorphism in the C-reactive protein (CRP) gene is associated with involvement of the...